Platelet-derived growth factor-AA-mediated functional angiogenesis in the rat epigastric island flap after genetic modification of fibroblasts is ischemia dependent.

BACKGROUND The aim of this study was to induce therapeutic angiogenesis in ischemically challenged flap tissue by means of gene transfer. METHODS Isogenic rat fibroblasts were retrovirally transfected to produce platelet-derived growth factor (PDGF)-AA. Stable gene expression was monitored by PDGF-AA enzyme-linked immunosorbent assay. Eighty animals were divided into 2 groups (1 and 2), each with 4 subgroups. The angiogenic target was a 7 x 7-cm epigastric island flap used as a necrosis model. Group 1 received flap treatment 1 week before flap elevation: 10(7) genetically modified fibroblasts, expressing PDGF-AA (genetically modified fibroblasts) plus 1 mL of Dulbecco's modified Eagle's medium (DMEM) (1A), 10(7) nonmodified fibroblasts (NMFB) plus 1 mL of DMEM (1B), 1 mL of DMEM (1C), and 1 mL of sodium chloride 0.9% (1D). All substances were injected at evenly distributed spots into the panniculus carnosus of the entire flap. Group 2 had the same flap treatment at the day of flap elevation. All flaps were sutured back. Seven days later, the flaps were harvested and examined both clinically, histologically, and immunohistochemically. RESULTS In vitro, the GMFB produced up to 117.9 +/- 57.2 ng of PDGF-AA/mL medium during a 4-day period, compared with 0.7 +/- 0.6 ng of PDGF-AA/mL medium produced by NMFB in the same time period. In vivo production of PDGF-AA in flaps amounted to 1.3 +/- 0.7 ng of PDGF-AA/1 microL flap tissue for group 1A and 1.7 +/- 1.1 ng of PDGF-AA/1 microL flap tissue for group 2A seven days after cell transplantation. Fibroblasts persisted in all flaps from groups 1A, 1B, 2A, and 2B without major inflammatory reaction. Clinically, group 2A developed significantly less flap necrosis compared with all other groups, including group 1A. Accordingly, only group 2A gave significant histologic and immunohistochemical evidence for enhanced angiogenesis within the flap tissue. CONCLUSIONS After retroviral gene transfer, isogenic rat fibroblasts produce high amounts of PDGF-AA in vitro. In vivo, PDGF-AA can be detected in flaps receiving genetically modified fibroblasts, which suggests survival of the implanted fibroblasts in this model. PDGF-AA produced by GMFB can induce flap angiogenesis only under ischemic conditions in this model. Transplantation of PDGF-AA-overexpressing fibroblasts results in higher flap survival in this model.

[1]  S. L. Warren,et al.  pp60(c-src) modulates microvascular endothelial phenotype and in vitro angiogenesis. , 2001, Experimental and molecular pathology.

[2]  H. Blau,et al.  VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.

[3]  E. Lakatta,et al.  Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. , 2000, Circulation.

[4]  H. Weinberg,et al.  Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis. , 2000, Plastic and reconstructive surgery.

[5]  A. Berger,et al.  Gentherapeutische Möglichkeiten in der plastischen Chirurgie , 2000, Der Chirurg.

[6]  M. Urken,et al.  Locally Administered Vascular Endothelial Growth Factor cDNA Increases Survival of Ischemic Experimental Skin Flaps , 1998, Plastic and reconstructive surgery.

[7]  F. Berthiaume,et al.  Genetically modified fibroblasts induce angiogenesis in the rat epigastric island flap , 1998, Langenbeck's Archives of Surgery.

[8]  E. Browne,et al.  Effect of Vascular Endothelial Growth Factor (VEGF) on Survival of Random Extension of Axial Pattern Skin Flaps in the Rat , 1996, Annals of plastic surgery.

[9]  J. Lo´pez,et al.  Evaluation of angiogenesis in delayed skin flaps using a monoclonal antibody for the vascular endothelium , 1995 .

[10]  R. Perlmutter,et al.  Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. , 1994, The Journal of clinical investigation.

[11]  R. Tompkins,et al.  Advances in recombinant retroviruses for gene delivery , 1993 .

[12]  J. Li,et al.  Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Manek,et al.  The oblique rat groin flap. , 1991, British journal of plastic surgery.

[14]  R. Mulligan,et al.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Ross,et al.  Platelet-derived growth factor in vivo: levels, activity, and rate of clearance , 1984 .

[16]  M. McGrath,et al.  The intravenous fluorescein test: use in timing of groin flap division. , 1979, The Journal of hand surgery.

[17]  T. Nakajima.  How soon do venous drainage channels develop at the periphery of a free flap? A study in rats. , 1978, British journal of plastic surgery.

[18]  N. Georgiade,et al.  THE VASCULARIZATION OF FREE FLAPS: A Clinical and Experimental Correlation , 1977, Plastic and reconstructive surgery.